Statement: More than 15 patients in cohort 1 of the primary trial experienced adverse events.
Primary_evidence: Adverse Events 1:   Total: 31/185 (16.76%)   Anemic Shock  [1]1/185 (0.54%)   Febrile Neutropenia  [2]13/185 (7.03%)   Febrile Neutropenia 2/185 (1.08%)   Febrile neutropenia  [3]3/185 (1.62%)   Neutrophil Count Decreased  [2]2/185 (1.08%)   Neutrophil Count Decreased  [3]2/185 (1.08%)   Neutrophil Count Decreased  [4]2/185 (1.08%)   Colon Diverticulitis 1/185 (0.54%)   Vomiting  [2]1/185 (0.54%)